SHANGHAI JUNSHI BIO YC1 Net Assets
SHANGHAI JUNSHI BIO YC1 net assets. Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) has net assets worth €6.07 Billion EUR (≈ $7.10 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.40 Billion ≈ $14.50 Billion USD) and total liabilities (€6.33 Billion ≈ $7.40 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SHANGHAI JUNSHI BIO YC1 equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.07 Billion |
| % of Total Assets | 48.98% |
| Annual Growth Rate | -7.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.96 |
Net Assets of SHANGHAI JUNSHI BIO YC1 (2021–2025)
Net assets of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025. This chart illustrates how SHANGHAI JUNSHI BIO YC1's net assets have evolved over time, based on quarterly financial data. See SHANGHAI JUNSHI BIO YC1 balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for SHANGHAI JUNSHI BIO YC1 (2021–2025)
The table below shows the annual net assets of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025. For live market cap and overall valuation, see SHANGHAI JUNSHI BIO YC1 (8SJ) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.07 Billion ≈ $7.10 Billion |
+2.07% |
| 2024-12-31 | €5.95 Billion ≈ $6.96 Billion |
-18.94% |
| 2023-12-31 | €7.34 Billion ≈ $8.58 Billion |
-25.06% |
| 2022-12-31 | €9.79 Billion ≈ $11.45 Billion |
+17.55% |
| 2021-12-31 | €8.33 Billion ≈ $9.74 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SHANGHAI JUNSHI BIO YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1116409000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SHANGHAI JUNSHI BIO YC1 Net Assets Breakdown (December 2025)
SHANGHAI JUNSHI BIO YC1 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €17.21 Billion | 284.62% |
| Total Equity | €6.05 Billion | 100.00% |
SHANGHAI JUNSHI BIO YC1 Competitors by Market Cap
The table below lists competitors of SHANGHAI JUNSHI BIO YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GEOPARK LTD. DL -001
F:G6O
|
$526.49 Million |
|
Suzhou Sunmun Technology Co Ltd
SHE:300522
|
$526.58 Million |
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
$526.61 Million |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
$526.62 Million |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
$526.28 Million |
|
Laurent-Perrier
PA:LPE
|
$526.05 Million |
|
Vatti Corp Ltd
SHE:002035
|
$525.92 Million |
|
Loctek Ergonomic Technology Corp Class A
SHE:300729
|
$525.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANGHAI JUNSHI BIO YC1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,878,551,000 to 6,047,090,000, a change of 168,539,000 (2.9%).
- Net loss of 840,910,000 reduced equity.
- New share issuances of 939,583,000 increased equity.
- Other factors increased equity by 69,866,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-840.91 Million | -13.91% |
| Share Issuances | €939.58 Million | +15.54% |
| Other Changes | €69.87 Million | +1.16% |
| Total Change | €- | 2.87% |
Book Value vs Market Value Analysis
This analysis compares SHANGHAI JUNSHI BIO YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €8.74 | €1.73 | x |
| 2022-12-31 | €9.67 | €1.73 | x |
| 2023-12-31 | €7.27 | €1.73 | x |
| 2024-12-31 | €5.97 | €1.73 | x |
| 2025-12-31 | €5.89 | €1.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANGHAI JUNSHI BIO YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.66%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 2.05x
- Recent ROE (-13.91%) is above the historical average (-20.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -9.03% | -17.85% | 0.36x | 1.39x | €-1.51 Billion |
| 2022 | -25.11% | -164.16% | 0.12x | 1.32x | €-3.34 Billion |
| 2023 | -31.82% | -151.85% | 0.13x | 1.58x | €-3.00 Billion |
| 2024 | -21.81% | -65.82% | 0.18x | 1.84x | €-1.87 Billion |
| 2025 | -13.91% | -33.66% | 0.20x | 2.05x | €-1.45 Billion |
Industry Comparison
This section compares SHANGHAI JUNSHI BIO YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANGHAI JUNSHI BIO YC1 (8SJ) | €6.07 Billion | -9.03% | 1.04x | $526.46 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more